Science Pub Corvallis offers cool presentations in an informal atmosphere where you can interact with experts and where there are no silly questions. No scientific background is required – just bring your curiosity, sense of humor, and appetite for food, drinks and knowledge!
Held on the second Monday of the month, 6 to 8 p.m. in the Old World Deli, 341 2nd St. in Corvallis, Science Pub is sponsored by the Oregon Museum of Science and Industry, the Downtown Corvallis Association and Terra magazine at Oregon State University.
No RSVP is necessary. Tell your friends and join us on Facebook to stay informed about upcoming guests. We hope to see you there! Check out photos from the May 13, 2013 Science Pub. You can also see recorded Science Pub events online. And if you can’t join us in Corvallis, check out science pubs by OSU-Cascades in Bend and by OMSI in Portland, Hillsboro, McMinnville and Eugene. The Center for Sustainable Materials Chemistry, an international research center led by Oregon State and the University of Oregon, is hosting science pubs at the Calapooia Brewery in Albany. Contact Andy Bedingfield (firstname.lastname@example.org) for dates and topics.
Do you fancy yourself an expert on science? Take the Science Pub quiz!
Next Science Pub, December 8, 2014
Treatments for Ebola: New approaches to infectious disease
Speaker: Patrick Iversen, research professor, Department of Environmental and Molecular Toxicology, Oregon State University
By now, the images and stories of the Ebola epidemic are depressingly familiar: health workers covered head-to-toe in protective clothing; clinics overflowing with the sick; anxious family members; assurances and predictions from the directors of health-care organizations..
As health-care agencies struggle to marshal an effective response, they are looking to an Oregon State University professor and Sarepta Therapeutics for help. Patrick Iversen was a senior vice president at Sarepta when he led a team that developed drugs to treat Ebola and a related virus known as Marburg. The company has completed Phase 1 clinical trials with the Ebola drug, known as AVI-7537. It would normally take years and millions of dollars to complete Phase 2 and 3 trials before it receives approval from the U.S. Food and Drug Administration.
At the Corvallis Science Pub, Iversen will review what scientists know about Ebola and how the new drug works. He’ll also discuss how the basis for Sarepta’s approach could signal a new way to treat infectious diseases.
Iversen received his Ph.D. in pharmacology at the University of Utah in 1984. He was a professor in the University of Nebraska College of Medicine and on the staff of the university’s Medical Center before moving to Corvallis to join AVI Biopharma Inc. in 1997. He is named as an inventor on 200 medical patents and is now a research professor in the Department of Environmental and Molecular Toxicology at Oregon State.
Upcoming Science Pubs
Sarina Saturn, assistant professor, OSU School of Psychological Science, will discuss perspectives on women in science.